Tweedy Browne on Bausch & Lomb

Author's Avatar
Jul 17, 2006
Bausch & Lomb. We purchased our shares in Bausch & Lomb after the shares declined precipitously following the discovery that a few users of one of their contact lens solutions were developing eye infections, which in a few instances had led to blindness. We believe the market overreacted to what appeared to be a fairly well contained problem, and that the shares represent solid value at our buy-in at $46 per share down from a high of $87 per share in July of 2005.Also check out: